FMISO-PET as Biomarker of Early Response to Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Abstract

Hypoxia is associated with resistance to radiation therapy and chemotherapy. Functional imaging of hypoxia in NSCLC before and after initiation of therapy could allow early assessment of tumor response and guide subsequent therapies. EGFR inhibition with the tyrosine kinase inhibitor erlotinib has been shown to reduce hypoxia in vivo. [18F]-fluoromisonidazole (FMISO) is a radiolabeled tracer that selectively accumulates in hypoxic cells.